Anika Therapeutics Inc Total Liabilities
Anika Therapeutics Inc total liabilities. Based on the latest financial reports, Anika Therapeutics Inc (ANIK) has total liabilities worth $46.19 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Anika Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Anika Therapeutics Inc (1993–2025)
Total liabilities of Anika Therapeutics Inc from 1993 to 2025. This chart illustrates how Anika Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Anika Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Anika Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daedalus Special Acquisition Corp.
NASDAQ:DSAC
|
USA | $11.71 Million |
|
Mahamaya Steel Industries Limited
NSE:MAHASTEEL
|
India | Rs-1.59 Billion |
|
Columbus Circle Capital Corp I Class A Ordinary Shares
NASDAQ:CCCM
|
USA | $676.71K |
|
DYNAM JAPAN HOLDINGS Co. Ltd
F:2DJ
|
Germany | €227.93 Billion |
|
Il Dong Pharmaceutical Co Ltd
KO:249420
|
Korea | ₩347.04 Billion |
|
Zhejiang Dilong New Material Co Ltd
SHE:002247
|
China | CN¥281.35 Million |
|
Beijing Piesat Information Technology Co Ltd
SHG:688066
|
China | CN¥3.81 Billion |
|
Karmarts Public Company Limited
BK:KAMART
|
Thailand | ฿1.49 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Anika Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Anika Therapeutics Inc.
Liquidity & Leverage Metrics
Anika Therapeutics Inc Total Liabilities Ratios Explained
Anika Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anika Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anika Therapeutics Inc (1993–2025)
The table below shows the annual total liabilities of Anika Therapeutics Inc from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $46.80 Million | -3.99% |
| 2024-12-31 | $48.75 Million | -16.48% |
| 2023-12-31 | $58.37 Million | -8.18% |
| 2022-12-31 | $63.56 Million | +5.15% |
| 2021-12-31 | $60.45 Million | -35.14% |
| 2020-12-31 | $93.20 Million | +120.18% |
| 2019-12-31 | $42.33 Million | +175.22% |
| 2018-12-31 | $15.38 Million | -19.58% |
| 2017-12-31 | $19.13 Million | +9.46% |
| 2016-12-31 | $17.47 Million | -29.83% |
| 2015-12-31 | $24.90 Million | +56.61% |
| 2014-12-31 | $15.90 Million | -22.09% |
| 2013-12-31 | $20.41 Million | -38.43% |
| 2012-12-31 | $33.14 Million | -12.97% |
| 2011-12-31 | $38.08 Million | -12.95% |
| 2010-12-31 | $43.75 Million | -9.91% |
| 2009-12-31 | $48.56 Million | +38.48% |
| 2008-12-31 | $35.06 Million | +42.91% |
| 2007-12-31 | $24.54 Million | +8.44% |
| 2006-12-31 | $22.63 Million | -8.49% |
| 2005-12-31 | $24.73 Million | -15.25% |
| 2004-12-31 | $29.18 Million | +650.19% |
| 2003-12-31 | $3.89 Million | +28.67% |
| 2002-12-31 | $3.02 Million | +7.49% |
| 2001-12-31 | $2.81 Million | +24.08% |
| 2000-12-31 | $2.27 Million | -66.67% |
| 1999-12-31 | $6.80 Million | +172.00% |
| 1998-12-31 | $2.50 Million | 0.00% |
| 1997-12-31 | $2.50 Million | +31.58% |
| 1996-12-31 | $1.90 Million | -13.64% |
| 1995-12-31 | $2.20 Million | -4.35% |
| 1994-12-31 | $2.30 Million | -20.69% |
| 1993-12-31 | $2.90 Million | -- |
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more